Search
Rectal
EAY191-E4 **11/30/23: EAY191-E4 is nearing the completion of its first stage of accrual, and no additional treatment assignments will be processed** **If biopsy needed, TBD at MBMC**
ComboMATCH Treatment Trial E4: Nilotinib and Paclitaxel in Patients with Prior Taxane-Treated Solid Tumors
URCC 22063
Longitudinal Observational Trial to Uncover Subtypes of Cancer Cachexia (LOTUS-CC)
EAY191 (ComboMATCH) **If biopsy needed, TBD at MBMC**
Molecular Analysis for Combination Therapy Choice
URCC 19075 **MBMC ONLY**
Multi-Center Randomized Controlled Phase II Trial of Exercise to Treat Chemotherapy-Induced Peripheral Neuropathy (CIPN)
ECOG-ACRIN EA2201 (JIT – IF A POSSIBLE PATIENT IS IDENTIFIED, NOTIFY CRA ASAP AS IT WILL TAKE TIME TO OPEN TRIAL THROUGH NCORP)
A Phase II Study of Neoadjuvant Nivolumab Plus Ipilimumab and Short-Course Radiation in MSI-H/dMMR Locally Advanced Rectal Adenocarcinoma
URCC-21038
Disparities in REsults of Immune Checkpoint Inhibitor Treatment (DiRECT): A Prospective Cohort Study of Cancer Survivors Treated with anti-PD-1/anti-PD-L1 Immunotherapy in a Community Oncology Setting
NSABP C-14 / CORRECT-MRD II
Second Colorectal Cancer Clinical Validation Study to Predict Recurrence Using a Circulating Tumor DNA Assay to Detect Minimal Residual Disease
A221805 **EFFECTIVE 3/31/23, at 7am CST, the Phase II portion of the study will permanently close to new patient accrual. Information regarding the status of the Phase III component will be sent upon completion of the Phase II analyses. If the analysis is positive, a reactivation notice will be distributed at the time A221805 opens to Phase III enrollment.**
Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II to Phase III Study
WF 1806
Myopenia and Mechanisms of Chemotherapy Toxicity in Older Adults with Colorectal Cancer: The M&M Study
URCC 18007
Randomized Placebo Controlled Trial of Bupropion For Cancer Related Fatigue
